Merck’s Keytruda (pembrolizumab) Receives FDA’s Accelerated Approval as a Monotherapy for Metastatic Small Cell Lung Cancer

Merck’s Keytruda (pembrolizumab) Receives FDA’s Accelerated Approval as a Monotherapy for Metastatic Small Cell Lung Cancer

Shots:

  • The approval is based on KEYNOTE-158 & KEYNOTE-028 studies result assessing Keytruda (200mg, IV) in patients with SCLC with disease progression on/after platinum-based CT, prior treated with 1L+ therapy
  • Collective results: ORR (19%); CRR (2%); PRR (17%); DOR @6mos. (94%); DOR @12mos. (63%); DOR @18mos. (56%)
  • Keytruda is an anti-PD-1 therapy, blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2 thereby activating T lymphocytes, affecting both tumor & healthy cells, being evaluated in 1000+ studies for multiple cancer

Click here to read full press release/ article | Ref: Merck | Image: Livemint